Encapsulated embryonic stem cell-derived NKX6.1-positive cells for diabetes

A line of human embryonic stem cells (hESCs) was differentiated into pancreatic progenitor cells expresseing high or low levels of NKX6.1 and loaded into a bilaminar Theracyte™ encapsulation devices. The devices were subcutaneously implanted into a diabetic mouse model. Only the cells expressing high levels of Nkx6.1 exhibited complete reversal of hyperglycemia.